OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
Last trade$0.7564
Day change+$0.0757 (+11.12%)
Day range$0.649 – $0.765
Volume916,890
Market cap$32M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$31.83M
Price / earnings
—
Price / book
-2.67×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.85×
Profitability
Earnings per share
-$0.84
Return on assets
-397.78%
Return on equity
330.43%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.01×
Current ratio
0.18×
Quick ratio
0.18×
Cash ratio
0.01×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.53M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OSTX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.5M
$2.82M
$3.19M
$3.12M
$2.34M
$3.69M
$2.1M
$1.23M
Research and development
$6.07M
$7.35M
$8.8M
$3.76M
$2.5M
$1.31M
$870.47K
$1.21M
Total operating expenses
$8.58M
$10.17M
$11.99M
$6.88M
$4.84M
$5M
$2.97M
$2.44M
Operating income
-$8.58M
-$10.17M
-$11.99M
-$6.88M
-$4.84M
-$5M
-$2.97M
-$2.44M
Interest expense
-$5.58K
-$75.34K
$0
$0
$0
$0
-$7.56K
-$437.84K
Income before taxes
-$8.63M
-$10.4M
-$13.46M
-$6.88M
-$4.54M
-$3.88M
-$2.99M
-$2.88M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$8.63M
-$10.4M
-$13.46M
-$6.88M
-$4.54M
-$3.88M
-$2.99M
-$2.88M
Net income attributable to common shareholders
-$8.63M
-$10.4M
-$13.46M
-$6.88M
-$4.54M
-$3.88M
-$2.99M
-$2.88M
EBITDA
-$8.45M
-$10.04M
-$11.86M
-$6.75M
-$4.73M
-$5M
-$4.39M
-$2.1M
Basic earnings per share
-$0.20
-$0.27
-$0.35
-$0.21
-$0.19
-$0.18
-$0.23
-$0.18
Diluted earnings per share
-$0.20
-$0.27
-$0.35
-$0.21
-$0.19
-$0.18
-$0.23
-$0.18
Recent news
Company coverage with links to the original publishers.
Institutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising cancer treatments with strong clinical data and FDA support, positioning themselves for potential M&A activity as major pharma companies seek differentiated assets.
Several biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.
Analysts forecast the global oncology drug market to exceed $900 billion by 2034, with biotech firms like Oncolytics, Teva, Citius, ADC Therapeutics, and OS Therapies driving cancer treatment innovation amid potential NCI funding cuts.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.